• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, Sept. 18

Drug-delivery company Ethypharm India has formalised an out-licensing deal and supply agreement with Ranbaxy for fixed-dose combination of Fenofibrate micronised 160 mg and Atorvastatin 10 mg. Ethypharm is a subsidiary of French company Ethypharm S.A. and the deal with Ranbaxy on the cholestrol drug is for the Indian market, a note from Ethypharm said. The agreement comes close after a similar deal that Ethypharm had signed in May with Ranbaxy for out-licensing and supply of painkiller drug Tramadol Flashtab.

The products will be supplied from Ethypharm's manufacturing facility near Mumbai as finished and packaged formulations and marketed and distributed by Ranbaxy under their brand name Storfib. Fenofibrate is a drug prescribed to lower triglycerides in cases of Hyperlipidemia while Atorvastatin is a drug widely used to manage cholesterol levels, the note said.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
McLeod Russel to raise up to $30 m through QIP

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line